Benchmark Upgrades Incyte After Stock Selloff
The recent downturn in Incyte Corporation’s (NASDAQ: INCY) share price offers an entry opportunity, with the FDA likely to approve ruxolitinib in chronic GVHD indication in September 2021, according to Benchmark.
